You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Mallinckrodt
Express Scripts
Colorcon
AstraZeneca

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Litigation Details for IN RE SEBELA PATENT LITIGATION (D.N.J. 2014)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in IN RE SEBELA PATENT LITIGATION
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for IN RE SEBELA PATENT LITIGATION (D.N.J. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-10-16 1 COUNT III: INFRINGEMENT OF U.S. PATENT NO. 7,598,271 43. Paragraphs 1-42 are incorporated… OF INFRINGEMENT OF U.S. PATENT NO. 7,598,271 50. Paragraphs 1-49 are incorporated… action for patent infringement of U.S. Patent Nos. 5,874,447 (the '"447 patent"), 7,598,2717,598,271 (the '"271 patent"), and 8,658,663 (the "'663 patent") (collectively, … the "patents-in-suit"), arising under the United States Patent Laws, Title 35, United States External link to document
2016-11-21 180 assert four patents, U.S. Patent Nos. 5,874,447 (the “447 patent”), 7,598,271 (the “271 patent), 8,658,…,663 (the “663 patent”), and 8,946,251 (the “251 patent”) (collectively, the “patents-in-suit”). …disputed claim terms are found in the ‘271 patent and the ‘251 patent. They are: • Crystalline…the patents-in-suit, as a drug for treating thermoregulatory dysfunction. See, e.g., ‘251 Patent at …methanesulfonate. See, e.g., ‘447 patent 1:27-33. Several of the patent claims at issue relate to different External link to document
2016-11-21 181 language of U.S. Patent Nos. 7,598,271 (the "271 patent") and 8,946,251 (the 251 patent). Signed by Judge… PACER Document IN RE SEBELA PATENT LITIGATION 16 October 2014 14…14 September 2017 2:14-cv-06414 830 Patent Defendant District Court, D. New External link to document
2017-08-11 297 between the ’743 application and U.S. patent No. 6,063,927 (the “’927 patent”), which was owned by SmithKline… (the “’663 patent”) and 8,946,251 (the “’251 patent”). A fourth patent, U.S. Patent No. 5,874,447 (the…each of the patents in suit. SOF 1[ 15. B. Patents in Suit i. The ’271 Patent The ’271 Patent, titled “…asserted three patents against Defendants: U.S. Patent Nos. 7,598,271 (the “’271 patent”), 8,658,663 (…Defendants: ’271 patent: Claim l. SOF 11 32. ’663 patent: Claims 1, 2, and 5. SOF 11 41. ’251 patent: Claims 1 External link to document
2017-09-14 308 infringed U.S. Patent Nos. 7,598,271 (the “271 patent”), 8,658,663 (the “663 patent”), and 8,946,251…claims of infringement of U.S. Patent No. 7,598,271 (the “271 patent”). 2. Judgment is entered…Order dated June 9, 2017, that: I. U.S. Patent No. 7.598.271 1. Judgment is entered in favor…271 patent, ‘663 patent, and ‘25 1 patent, and that the ‘271 patent, ‘663 patent, and ‘251 patent are…271 patent, claims 1-5 of the ‘663 patent, and claims 1, 2,4,9, 10, 11, and 12 of the ‘251 patent, under External link to document
2014-11-07 5 action for patent infringement of U.S. Patent Nos. 5,874,447 (the “’447 patent”), 7,598,271 (the ‘‘’271…for alleged patent infringement of U.S. Patent Nos. 5,874,447 (the “’447 patent”), 7,598,271 (the ‘‘’271…in and to U.S. Patent Nos. 5,874,447 (the “’447 patent”), 7,598,271 (the ‘‘’271 patent”), and 8,658,663… COUNT III: INFRINGEMENT OF U.S. PATENT NO. 7,598,271 43. Paragraphs 1-42 are incorporated… OF INFRINGEMENT OF U.S. PATENT NO. 7,598,271 50. Paragraphs 1-49 are incorporated External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
McKinsey
Boehringer Ingelheim
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.